Linagliptin-Induced Arthralgia-Reference-Cited by-同舟云学术

Linagliptin-Induced Arthralgia

Published:2022-01-01 Issue:1 Volume:40 Page:109-112
ISSN:0891-8929
Container-title:Clinical Diabetes
language:en
Short-container-title:

Author:

Nigro Stefanie C.¹^ORCID,Goldman Jennifer D.²

Affiliation:

1. University of Connecticut School of Pharmacy, Storrs, CT

2. MCPHS University, Boston, MA

Publisher

American Diabetes Association

Subject

Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://diabetesjournals.org/clinical/article-pdf/40/1/109/638765/diaclincd200110.pdf

Reference14 articles.

1. A method for estimating the probability of adverse drug reactions;Naranjo;Clin Pharmacol Ther,1981

2. Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes: preclinical biology and mechanisms of action;Drucker;Diabetes Care,2007

3. The nonglycemic actions of dipeptidyl peptidase-4 inhibitors;Kim;BioMed Res Int,2014

4. 2. Pharmacologic approaches to glycemic treatment: Standards of Medical Care in Diabetes—2020;American Diabetes Association;Diabetes Care,2020

5. U.S. Food and Drug Administration . FDA drug safety communication: FDA warns that DPP-4 inhibitors for type 2 diabetes may cause severe joint pain. Available from https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-warns- dpp-4-inhibitors-type-2-diabetes-may-cause-severe-joint-pain. Accessed 5 January 2020

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety of Linagliptin in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis of Randomized Clinical Trials;Therapeutic Innovation & Regulatory Science;2024-04-18